| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 959.00M | — |
| Operating expense | — | — |
| Net income | 144.40M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, NB3.F returned +13.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +8.0% |
| 1 year | +13.5% |
| 5 years | +61.4% |
| 10 years | +200.8% |
| All-time high | €147.85 (Jun 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in NB3.F would be worth today ›No. Neurocrine Biosciences, Inc. has not paid a dividend in the past 12 months.
Neurocrine Biosciences, Inc. is part of the Healthcare sector.
Neurocrine Biosciences, Inc. has a market cap of 13.26B EUR, based on the latest quote.
Neurocrine Biosciences, Inc. is expected to report earnings around Oct 28, 2026. That date is an estimate and has not been confirmed by the company.
